This grant opportunity, a collaboration between Pfizer and the American College of Emergency Physicians (ACEP), seeks proposals for quality improvement initiatives. The focus is on enhancing the safe management of patients diagnosed with migraine in the emergency department setting. The goal is to support clinical program development that addresses barriers to evidence-based management, disposition, and follow-up for this patient population.

Funding Opportunity Details

This program aims to support projects focused on clinical program development. These projects should overcome barriers to safe, evidence-based management, disposition, and follow-up of migraine patients in the ED. The initiatives should demonstrate improved patient safety, physician satisfaction, and/or patient satisfaction.

Projects should pinpoint and tackle obstacles and deficiencies concerning migraine management in the ED. This includes improving patient experience, outcomes of novel treatments, and access to follow-up care. System-based changes are highly encouraged within the project design.

Individual projects can request up to $200,000 USD, inclusive of all direct, overhead, and indirect costs. The intent is to support 3 to 4 projects. The maximum project length is 2 years.

Eligibility Criteria

Eligible applicants include medical, dental, nursing, allied health, and/or pharmacy professional schools. Healthcare institutions (both large and small), professional organizations, and government agencies are also eligible. These entities must have a mission related to healthcare improvement.

Only organizations are eligible to receive grants, not individuals or medical practice groups. Collaborations within and between institutions are encouraged, provided all partners have a relevant role. The requesting organization must have a key role in the project.

• The applicant must be the Project Lead/Principal Investigator (PI) or an authorized designee.
• The Project Lead/PI must be an employee or contractor of the requesting organization.
• Requesting organization must be legally able to receive award funding directly from Pfizer Inc.

Key Focus Areas

The primary area of interest for this RFP is migraine. The specific focus is on improving the quality of care for patients with migraines in the emergency department setting. This includes decreased cost, decreased length of stay, decreased return visits, improved pain control, improved time to pain control, and decreased testing.

Projects should be evidence-based (education and/or quality improvement) and follow generally accepted scientific principles. Projects with the maximum likelihood to directly impact patient care will be given high priority. Multi-disciplinary collaborations are encouraged when appropriate.

Target audiences include emergency physicians treating adult patients presenting with symptoms of migraine in the ED. Projects that include an overt description of system changes will be given high priority. Educational efforts for grantees and patients may be appropriate components.

Submission and Review Process

The submission deadline is 29 SEP 2025. Applications submitted after this date will not be reviewed. The anticipated grant award notification date is 31 OCT 2025, with an anticipated project start date in JAN 2026.

To submit, go to www.cybergrants.com/pfizer/QI and sign in. First-time users should click “Create your password”. Complete all required sections of the online application and upload the proposal in the Proposal/Protocol field. Select "Yes" for "Competitive Grant?" and choose the appropriate program name and primary area of interest.

Grant requests are reviewed by an expert review panel (ERP). All applicants will be notified via email. Applicants may be asked for additional clarification during the review period. If approved, the institution will be required to enter into a written grant agreement with Pfizer.

Recommended Research Topics

Based on the scope of the call or grant, here are some relevant research topics for academic research areas:

• Improving acute migraine treatment protocols in the ED
• Reducing opioid prescriptions for migraine in the ED
• Enhancing patient follow-up care post-ED visit for migraine
• Addressing disparities in migraine care in the ED
• System-based changes to improve migraine management in the ED

Important Dates and Monetary Range

The anticipated project end date is JAN 2028. Individual projects requesting up to $200,000 USD will be considered. The estimated total available budget related to this RFP is $600,000 USD.

Award amounts include direct costs, institutional overhead costs (capped at 28% per Pfizer policy), and indirect costs. The amount of the grant Pfizer will be prepared to fund for any project will depend upon the expert review panel’s evaluation of the proposal and costs involved.

Grants will be distributed following a fully executed agreement and submission of Final Protocol, Documentation of IRB/IEC Approval, Regulatory Approval (if applicable), Exemption or Waiver.